Whole body hyperthermia in adjuvant therapy of children with renal cell carcinoma

被引:18
|
作者
Ismail-Zade, RS
Zhavrid, EA
Potapnev, MP
机构
[1] Belarusian Ctr Pediat Oncol & Haemotol, Minsk 223040, BELARUS
[2] Res Inst Oncol & Med Radiol, Minsk, BELARUS
关键词
doxorubicin; interferon-alpha; renal cell carcinoma; whole body hyperthermia;
D O I
10.1002/pbc.20299
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Whole body hyperthermia (WBH) in combination with chemotherapy has been proven to be effective in some patients with advanced malignancies. However, only limited experience exists regarding the application of WBH with chemotherapy in children. We present the results of applying WBH and chemotherapy in five children with advanced renal cell carcinoma (RCC). WBH (3 hr, 41.8-42.5 degrees C) combined with doxorubicin (50 mg/m(2)) and interferon-alpha (3 MU/m(2)) were applied to patients after nephrectomy and lymph node dissection. Each patient received three to eight courses of treatment three times weekly. All children tolerated the combined therapy well without complications. Follow-up of 7-68 months (median: 22 months) showed no tumor progression in patients with locoregional (n = 3) and metastatic (n = 2) disease. WBH with moderate dose doxorubicin and INF-alpha might be a feasible treatment option in childhood RCC. (c) 2005 Wiley-Liss, Inc.
引用
收藏
页码:679 / 681
页数:3
相关论文
共 50 条
  • [41] Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma
    Powles, Thomas
    Burgents, Joseph E.
    Xu, Lei
    Choueiri, Toni K.
    [J]. LANCET ONCOLOGY, 2023, 24 (01): : E1 - E2
  • [42] Evaluation of renal cell carcinoma with whole body FDG PET.
    Hoh, CK
    Figlin, RA
    Belldegrun, A
    Moon, DH
    Franklin, J
    Phelps, ME
    Maddahi, J
    [J]. JOURNAL OF NUCLEAR MEDICINE, 1996, 37 (05) : 621 - 621
  • [43] Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?
    Mollica, Veronica
    Rizzo, Alessandro
    Di Nunno, Vincenzo
    Santoni, Matteo
    Cheng, Liang
    Lopez-Beltran, Antonio
    Scarpelli, Marina
    Cimadamore, Alessia
    Montironi, Rodolfo
    Massari, Francesco
    [J]. TRANSLATIONAL ANDROLOGY AND UROLOGY, 2021, 10 (03) : 1582 - +
  • [44] Adjuvant therapy for high-risk renal cell carcinoma patients
    Kunkle D.A.
    Haas N.B.
    Uzzo R.G.
    [J]. Current Urology Reports, 2007, 8 (1) : 19 - 30
  • [45] Adjuvant Therapy in Renal Cell Carcinoma-Past, Present, and Future
    Janowitz, Tobias
    Welsh, Sarah J.
    Zaki, Kamarul
    Mulders, Peter
    Eisen, Tim
    [J]. SEMINARS IN ONCOLOGY, 2013, 40 (04) : 482 - 491
  • [46] Adjuvant Therapy in Renal Cell Carcinoma: Current Status and Future Directions
    Kazarian, Austin G.
    Chawla, Neal S.
    Muddasani, Ramya
    Pal, Sumanta K.
    [J]. KIDNEY CANCER, 2021, 5 (01) : 9 - 20
  • [47] Adjuvant therapy in renal-cell carcinoma: Is it prime time yet?
    Dimitriadis, John
    Bamias, Aristotelis
    [J]. TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S360 - S362
  • [48] Adjuvant therapy with activated T cells for patients with renal cell carcinoma
    LeFever, A
    Treisman, J
    Hanson, J
    [J]. JOURNAL OF IMMUNOTHERAPY, 2003, 26 (06): : S20 - S21
  • [49] Adjuvant therapy in pediatric patients with completely resected renal cell carcinoma
    Geller, JI
    Dome, JS
    [J]. PEDIATRIC BLOOD & CANCER, 2006, 46 (04) : 527 - 527
  • [50] Adjuvant therapy in renal cell carcinoma: is resection still solely enough?
    El Gharib, Khalil
    [J]. FUTURE ONCOLOGY, 2021, 17 (06) : 633 - 636